STOCK TITAN

Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells Fargo Securities Healthcare Conference taking place in Everett, MA from September 7-9, 2022.

Fireside Chat Details:


 Date:Thursday, September 8, 2022
   
 Time:11:35 am -12:05 pm ET
   
 Presenters:
Ian Mortimer, President and CEO
Chris Von Seggern, CCO 


A webcast of the fireside chat will be available on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com


Xenon Pharmaceuticals Inc

NASDAQ:XENE

XENE Rankings

XENE Latest News

XENE Stock Data

3.28B
69.56M
0.38%
99.99%
3.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BURNABY

About XENE

xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.